7
, alphaglucosidase inhibitors 8 , sodium-glucose co-transporter 2 (SGLT2) inhibitors 9 and bile acid sequestrants 10 
however, these therapies each have their limitations and drawbacks. In particular, although the most widely used drug, metformin, is known to decrease hepatic gluconeogenesis, it does not have a well-defined molecular target 4 and is associated with gastrointestinal side effects 11 . Other classes of drugs are also accompanied by side effects, and may cause hyperinsulinaemia, sometimes resulting in hypoglycaemia [12] [13] [14] . Novel therapeutic approaches are therefore warranted.
Existing diabetes drugs target only a subset of the potentially druggable pathways that regulate glucose homeostasis, particularly in the liver 15 . As the chief producer of the glucose that is released to the circulation, the liver is an especially important organ in controlling blood sugar levels 16 . Moreover, in addition to its ability to produce glucose, the liver can store glucose as glycogen or utilize glucose as a carbohydrate fuel. Leveraging novel targets for decreasing liver glucose production or promoting liver glucose storage may enable more efficient suppression of diabetic symptoms. Such agents would probably be used combinatorially with existing drug therapies when enhanced suppression of blood glucose levels is necessary, and may enable the use of lower concentrations of individual drugs, thereby limiting side effects.
A small number of liver-targeted approaches, which aim to reduce gluconeogenesis or promote glycogen storage, are already being investigated in the clinic. These include glucokinase activators [17] [18] [19] [20] [21] [22] [23] [24] , glycogen phosphorylase inhibitors [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] , glucagon receptor antagonists [35] [36] [37] [38] [39] [40] [41] , fructose 1,6-bisphosphatase (FBPase) inhibitors [42] [43] [44] and protein tyrosine phosphatase 1B (PTP1B) inhibitors [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] 
Type 2 diabetes
A chronic disease of aberrant glucose homeostasis that is characterized by elevated blood glucose levels and insulin resistance.
Sulfonylureas
Type 2 diabetes drugs that stimulate insulin secretion from the pancreas through inhibition of K ATP channels in β-cells.
Thiazolidinediones
Insulin-sensitizing type 2 diabetes drugs that act as peroxisome proliferatoractivated receptor-γ (PPARγ) agonists (also known as glitazones).
Targeting hepatic glucose metabolism in the treatment of type 2 diabetes
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Abstract | Type 2 diabetes mellitus is characterized by the dysregulation of glucose homeostasis, resulting in hyperglycaemia. Although current diabetes treatments have exhibited some success in lowering blood glucose levels, their effect is not always sustained and their use may be associated with undesirable side effects, such as hypoglycaemia. Novel antidiabetic drugs, which may be used in combination with existing therapies, are therefore needed. The potential of specifically targeting the liver to normalize blood glucose levels has not been fully exploited. Here, we review the molecular mechanisms controlling hepatic gluconeogenesis and glycogen storage, and assess the prospect of therapeutically targeting associated pathways to treat type 2 diabetes.
. The liver is a major metabolic organ, and among its many functions it is chiefly responsible for gluconeogenesis (with the kidneys contributing an average 20% to glucose release 56 , and the gut supplying up to 15-20% 57 ) and glycogenolysis 58 . Gluconeogenesis and glycogenolysis by the liver lead to glucose release into the blood and a rise in blood glucose levels, with subsequent uptake of glucose by peripheral tissues, including the kidney, skeletal muscle, splanchnic organs and adipose tissue 59 (FIG. 1) .
Following feeding, postprandial insulin is secreted from pancreatic β-cells to directly inhibit glycogenolysis and increase glycogen synthesis 60, 61 , and to indirectly inhibit gluconeogenesis through suppression of glucagon and inhibition of adipose free fatty acid release 62 . Insulin also preferentially increases uptake of glucose by peripheral tissues 63 . Conversely, during periods of fasting, glucagon is secreted from pancreatic α-cells to increase gluconeogenesis and glycogenolysis in the liver 64 . Insulin levels also fall, and peripheral tissues utilize proportionately less glucose as fuel relative to fatty acids. In the 24 hours following absorption of a meal, glycogenolysis in the liver substantially contributes to the release of glucose into the circulation 65, 66 . The nexus of gluconeogenesis and glycogenolysis lies at glucose-6-phosphate, which is a phosphorylated form of glucose that cannot be exported by the cell until it is dephosphorylated by glucose-6-phosphatase (G6Pase; encoded by G6PC) (FIG. 2) . In gluconeogenesis, the substrates lactate, amino acids and glycerol are used by the liver to generate glucose-6-phosphate 67 . During glycogenolysis, glycogen is broken down and converted to glucose-6-phosphate. Glycogen, which consists of polymerized glucose, serves as a readily mobilized storage pool of carbohydrate fuel, which can be phosphorylated and quickly used to generate glucose when needed.
Normally, glucose production and uptake are kept in balance to maintain glucose homeostasis and a fasting blood glucose range of 70 to 90 mg per dl in humans 68 . Type 2 diabetes develops when insufficient insulin is produced to maintain this level of blood glucose, generally as a combined result of insulin resistance in peripheral tissues and β-cell dysfunction, leading to persistently elevated blood glucose levels or hyperglycaemia
68
. As diabetes is a chronic condition, its progression is characterized by advanced β-cell failure 69 . Additionally, aberrantly high levels of glucagon can persist in patients with diabetes, leading to elevated rates of gluconeogenesis and glycogenolysis in the liver that contribute to hyperglycaemia 70, 71 . The contribution of gluconeogenesis to glucose production is also proportionately larger in patients with diabetes than in normal individuals 72 . Moreover, the ability of patients with diabetes to store glycogen may be decreased compared to healthy individuals, which also enhances postprandial hyperglycaemia 73 . Prolonged hyperglycaemia during diabetes causes vascular dysfunction, which damages major organs including the kidneys, brain, heart, blood vessels and eyes 74 . Thus, treating the hyperglycaemia associated with diabetes is of the utmost importance in these patients.
Modulating liver glucose metabolism
Overall, an imbalance in the release of glucose from the liver and its uptake from peripheral tissues can lead to the persistent hyperglycaemia that is a major contributing factor to diabetes development. Therefore, drugs to treat type 2 diabetes can be aimed at maintaining normal blood glucose levels through inhibition of gluconeogenesis and/or glycogenolysis in the liver, or through stimulation of glucose uptake into tissues. The most commonly used type 2 diabetes therapy, metformin, is known to decrease hepatic gluconeogenesis; however, the precise molecular mechanisms of this agent have After feeding, pancreatic β-cells release insulin to inhibit gluconeogenesis and glycogenolysis in the liver, decreasing glucose output to the circulation. Insulin also acts at peripheral tissues to increase glucose uptake, resulting in decreased blood glucose levels. During fasting, pancreatic α-cells release glucagon to increase gluconeogenesis and glycogenolysis in the liver, increasing circulating blood glucose levels. In the diabetic state, insulin action is decreased at the liver and/or peripheral tissues, and glucagon action is enhanced, leading to increased hepatic gluconeogenesis and glycogenolysis, increased glucose release to the circulation, repressed glucose uptake into peripheral tissues, and increased blood glucose levels.
not been well defined 4 
. Moreover, metformin can cause various side effects and it typically must be used in combination with other drugs to achieve long-term suppression of hyperglycaemia 11, 75 . Other liver-targeted agents that have been or are currently being investigated in clinical trials include: activators of glucokinase (which converts glucose to glucose-6-phosphate in the first step of glycolysis) [17] [18] [19] [20] [21] [22] [23] , inhibitors of FBPase (which converts fructose-1,6-bisphosphate to fructose-6-phosphate in gluconeogenesis) [42] [43] [44] , inhibitors of PTP1B (which is a negative regulator of the insulin signalling pathway) [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] and inhibitors of glycogen phosphorylase (which catalyses the rate-limiting step in glycogenolysis) [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] , as well as antagonists of the glucagon receptor [35] [36] [37] [38] [39] [40] [41] . However, so far, no agents in these categories have received regulatory approval. The development of novel agents aimed at targeting gluconeogenesis and glycogen breakdown in the liver may provide effective alternative treatment options for diabetes. Potential therapeutic strategies include the direct targeting of specific metabolic enzymes of gluconeogenesis and glycogenolysis, or of regulators of these processes.
Glucokinase activation
Glucokinase, an enzyme that is predominately expressed in the liver and pancreas, may be activated to inhibit gluconeogenesis. Unfortunately, several early studies with direct allosteric glucokinase activators, such as AZD1656 (AstraZeneca) 17 , were abandoned during the clinical phases of research owing to a decline in efficacy of the compounds over time, as well as hypoglycaemic effects 18 . However, several glucokinase activators remain in clinical development 18 . The liver-selective glucokinase inhibitor PF-04991532 (Pfizer) exhibited favourable glycaemic effects in diabetic rats 19 , but newer findings indicated the presence of oxidative metabolites of the compound in human plasma 20 , which will require further careful examination if development is continued. In gluconeogenesis, lactate and amino acids are first converted to pyruvate, either directly or indirectly through tricarboxylic acid (TCA) cycle intermediates. Pyruvate is then shuttled from the cytosol into the mitochondria where it is used to generate oxaloacetate by pyruvate carboxylase. Oxaloacetate is converted to aspartate, exported from the mitochondria and re-converted to oxaloacetate, which is then converted into phosphoenolpyruvate (PEP) by PEP carboxylase (PEPCK). PEP is catalytically altered to fructose 1,6-bisphosphate, and glycerol can also enter gluconeogenesis through conversion to fructose-1,6-bisphosphate. Fructose-1,6-bisphosphate is then altered to fructose-6-phosphate by fructose-1,6-bisphosphatase (FBPase), then to glucose-6-phosphate by phosphohexose isomerase. Finally, the phosphate on glucose-6-phosphate is removed by the liver-specific enzyme glucose-6-phosphatase (G6Pase) to generate glucose, which can be exported to the circulation. During glycogenolysis, the glucose residues in glycogen are phosphorylated by glycogen phosphorylase to produce glucose-1-phosphate, then glucose-6-phosphate through phosphoglucomutase 92 . The reverse reaction is catalysed by glycogen synthase, which generates glycogen from UDP-glucose that is converted from glucose-1-phosphate by glucose-1-phosphate uridyltransferase. As in gluconeogenesis, the glucose-6-phosphate produced through glycogenolysis is converted to glucose by G6Pase, and released to the circulation. Enzymes that have been investigated for drug targeting are highlighted in red, and compounds that target these enzymes are highlighted in blue.
More recent clinical studies using the glucokinase activators piragliatin (Roche) and AMG 151 (Amgen; previously Array BioPharma (ARRY-403)) demonstrated that both agents resulted in hypoglycaemia, with a slight increase in circulating triglycerides for the latter 21, 22 . The outcomes of a 6-month phase II clinical trial with the liver-selective glucokinase activator TTP399 (Trans Tech Pharm) are pending following promising shortterm effects, including glucose lowering after 6 weeks without hypoglycaemia or increased plasma lipids 24 . Another approach to activating glucokinase is to inhibit its binding to glucokinase regulatory protein (GKRP). GKRP binds cytoplasmic glucokinase when glucose levels decrease, sequestering glucokinase in the nucleus in its inactive form. The benefit of this approach is that liver-specific GKRP inhibition decreases blood glucose levels without the risk of hypoglycaemia that can result from activating glucokinase or inhibiting pancreatic GKRP 76 . The piperazine compound AMG-3969 dissociated glucokinase and GKRP in rat livers, and decreased blood glucose levels in diabetic mice but not in normoglycaemic mice 23 . These findings suggest that GKRP inhibitors may represent promising candidates for clinical investigation.
PTP1B inhibition
Insulin exerts suppressive effects on glucose production by promoting insulin receptor phosphorylation, which triggers downstream signalling 77 . PTP1B dephosphorylates the insulin receptor, opposing the action of insulin. As phosphorylation of the insulin receptor is decreased in type 2 diabetes 78 , PTP1B is an attractive diabetes drug target. Mice deficient in PTP1B display enhanced hepatic insulin sensitivity, as indicated by increased phosphorylation of the insulin receptor in the liver; furthermore, these mice are resistant to gaining weight on a high-fat diet 79 . Mice in which PTP1B is specifically deleted in the liver display enhanced hepatic insulin signalling, improved glucose tolerance and homeostasis, and increased suppression of hepatic glucose production in insulin-resistant and high-fat-diet-induced obesity models 80, 81 . These and other studies further justify the targeting of hepatic PTP1B for diabetes treatment 82 . Studies in monkeys and mice have reported that ISIS 113715 (ISIS Pharmaceuticals), an antisense oligonucleo tide targeting PTP1B that is not liver-specific, reduces fasting concentrations of glucose while improving insulin sensitivity and decreasing hepatic triglyceride accumulation 46, 47 . ISIS 113715 has shown promising effects in decreasing fasting blood glucose levels in combination with sulfonyl ureas in a phase II clinical trial involving patients with type 2 diabetes 45 . Targeting PTP1B with small-molecule inhibitors has also been attempted. Ertiprotafib (formerly Wyeth Pharmaceuticals; now Pfizer) showed initial promise by lowering blood glucose levels when it was orally administered to mice 48 and progressed to a phase II clinical trial. Further studies also indicated decreased insulin levels, along with lowered triglyceride and free fatty acid levels; however, reports indicate that these outcomes were likely to be due to the off-target effects of ertiprotafib, which include activation of peroxisome proliferator-activated receptor-α (PPARα) and PPARγ 49 , and potent inhibition of IκB kinase β (IKKβ) 50 . Phase II trials with ertiprotafib were discontinued, probably owing to its lack of in vivo efficacy, coupled with unwanted side effects 49 . Trodusquemine (MSI-1436), developed by Genaera Corporation (formerly Magainin Pharmaceuticals), is a spermine analogue that was initially observed to modulate body weight, glucose homeo stasis and serum cholesterol levels in ob/ob mice 51 , and was later determined to selectively inhibit PTP1B 52 . In 2013, trodusquemine was in phase II clinical trials for the treatment of obesity and diabetes, but development was discontinued for unknown reasons 53 . More recently, a chemical biology approach has uncovered an allosteric mechanism of PTP1B inhibition by trodusquemine 54 . Carefully designed small molecules that allosterically target PTP1B could enhance specificity, which could improve in vivo efficacy and reduce unwanted off-target effects.
Glycogen synthesis stimulation
Glycogen phosphorylase inhibition. One method to inhibit glucose release by the liver is to increase its storage as glycogen. In patients with diabetes, hepatic glycogen synthesis is impaired 83 and the stimulation of glycogen synthesis in skeletal muscle by insulin is stunted, contributing to insulin resistance 84 . Ectopic lipid accumulation in the liver and skeletal muscle leads to diminished insulin signalling and decreased hepatic glycogen synthesis 85 . Human liver glycogen phosphorylase inhibitors can increase glycogen synthesis by interfering with glucose-6-phosphate generation during glycogenolysis 26 . A major appeal of these compounds is that they inhibit the enzyme at elevated blood glucose levels, but their potency diminishes when blood glucose levels are lowered, decreasing the likelihood of developing hypoglycaemia 27 . Indeed, treatment of db/db mice with the dihydropyridine diacid glycogen phosphorylase inhibitor U6751 or treatment of ob/ob mice with CP-91149 lowered blood glucose levels without producing hypoglycaemia, but had no effect on blood glucose levels in normal mice 28, 29 . On a molecular level, indole-2-carboxamides act as allosteric inhibitors that bind to the indole site at the dimer interface of glycogen phophorylase to stabilize its inactive conformation, and also synergize with other inhibitors such as glucose 30 . Notably, the half-maximal inhibitory concentration (IC 50 ) of a compound designed to fit into both chloroindole binding pockets of glycogen phosphorylase was only 6 nM 30 . The glycogen phosphorylase inhibitor FR258900 was discovered in a screen for increased glycogen synthesis in rat primary hepatocytes 86 . FR258900 is a 23-carbon pentanedioic acid that binds to the AMP site of glycogen phosphorylase and stabilizes its inactive conformation 87 . This compound significantly decreased plasma glucose levels and increased hepatic glycogen levels in db/db mice and streptozotocin-induced diabetic mice 31 , but its long-term effects or actions in other tissues were not studied. CP-316819 is an indole carboxamide compound 32 that decreased hepatic glucose output in fasting dogs with basal or elevated glucagon levels 33 , although a thorough analysis of its potential effects on other tissues was not performed. Another commercially available glycogen phosphorylase inhibitor, BAY R3401, which acts by a similar mechanism as an indole carboxamide, also successfully decreased hepatic glucose output and plasma glucose levels in fasting dogs 34 . Limited clinical studies were performed with CP-316819, which showed lowering of peak hyperglycaemia after a glucagon challenge in normal human subjects 25 . A related compound, CP-368962, was able to lower blood glucose levels in a dose-dependent manner in individuals with type 2 diabetes, but the effect was lost after 4 weeks of treatment, demonstrating a lack of durability 25 . However, glycogen phosphorylase has five different ligand binding sites, including its catalytic and AMP-binding sites, revealing several possible methods for targeting its enzyme activity 88 . Thus, although glycogen phosphorylase inhibitors may have thus far failed owing to lack of durability, alternative approaches may enable the development of an inhibitor that is able to overcome this barrier.
A potential problem associated with targeting glycogen phosphorylase is that this enzyme is also present in the skeletal muscle, where it is needed to support energetic deficits 89 . The issue of tissue selectivity could be abated by selecting an inhibitor that is more potent against the liver isoform 90 . However, tissue selectivity may not be a substantial confounding issue, as a study in rat gastrocnemiusplantaris-soleus muscle suggested that treatment with glycogen phosphorylase inhibitors did not deplete skeletal muscle function 89 . Additionally, glycogen phosphorylase inhibitors may be beneficial to cardiac muscle, where they can reduce glycolysis and proton production, which are harmful during myocardial ischaemia 91 .
Glycogen synthase activation. Glycogen synthesis can also be targeted through the activation of glycogen synthase 92 . Although inhibition of glycogen phosphorylase
Box 1 | Current type 2 diabetes drugs
The most commonly used diabetes therapy is metformin (N,N-dimethylbiguanide), a biguanide compound that decreases gluconeogenesis 237 . Its popularity stems from its ability to lower blood glucose levels without inducing hypoglycaemia or weight gain, while maintaining an excellent safety profile 4 . However, the molecular mechanism of metformin has not been well defined. A generally acknowledged site of action of metformin is the mitochondria, where it partially inhibits complex I 238, 239 to decrease cellular energy and gluconeogenesis 240 . How a decrease in cellular energy (as represented by an increase in the AMP:ATP ratio) causes a change in gluconeogenesis is unclear. Some reports have indicated that activation of AMP-activated protein kinase (AMPK) is necessary 241 . Others have found that AMPK is not needed, but instead the accumulation of AMP:ATP directly inhibits gluconeogenic flux 240 and inhibits adenylyl cyclase to decrease cyclic AMP and activation of protein kinase A (PKA) 242 . Metformin has also been reported to inhibit mitochondrial glycerophosphate dehydrogenase (mGPD), which blocks the glycerophosphate shuttle and alters the hepatic redox state to decrease the conversion of lactate and pyruvate to glucose and therefore decrease the rate of gluconeogenesis 243 . In addition to affecting gluconeogenesis, metformin decreases tissue lipid storage through AMPK phosphorylation and inactivation of acetyl-coA carboxylase (ACC), which then can improve insulin sensitivity and decrease blood glucose levels 244 . Although considered safe, metformin is accompanied by gastrointestinal side effects including nausea, which may result from its effects on multiple tissues 11 . Additionally, the effect of metformin on glycaemic control is typically reduced over time, requiring combined treatment with other drugs 75 . Several other classes of drugs affect insulin secretion from the pancreas or uptake of glucose into tissues. Sulfonylureas and meglitinides/d-phenylalanine increase insulin secretion by closing K ATP channels in pancreatic β-cells 5, 245 . Although they are effective at lowering blood glucose levels, these agents can cause hypoglycaemia, epithelial damage or β-cell exhaustion or apoptosis 12 . Glucagon-like peptide 1 (GLP1) is a gut-secreted hormone that stimulates insulin and impairs glucagon secretion, and its actions can be increased through direct agonism or by inhibition of dipeptidyl peptidase 4 (DPP4), which leads to enhanced GLP1 secretion 6 . Side effects of GLP1 agonists include nausea, diarrhoea and headaches, whereas DPP4 inhibitors may cause upper-respiratory-tract infections and headaches 246 . Aside from the potential side effects, the insulin-stimulating action of sulfonylureas and GLP1 agonists may not be the best course of treatment for diabetes, as this can result in weight gain, and hyperinsulinaemia has been associated with comorbidities including cardiovascular disease and cancer 13, 14 . However, no substantial link has yet been found between the use of these drugs and the incidence of these comorbidities.
The thiazolidinedione (TZD) class of drugs act as agonists for peroxisome proliferator-activated receptor-γ (PPARγ) in order to increase glucose uptake into peripheral tissues, thereby increasing insulin sensitivity 7 . Although often effective, this drug class has potential complications, including increased risks of myocardial infarction, skeletal fractures and bladder cancer 7 . Alpha-glucosidase inhibitors lower blood glucose levels by a different method, blocking the digestion of carbohydrates through the inhibition of enterocyte enzymes that cleave oligosaccharides to monosaccharides 8 . These drugs can be useful particularly if postprandial glucose absorption is a concern, although they are often associated with undesirable gastrointestinal effects.
Another approach to lowering blood glucose levels is through sodium-glucose co-transporter 2 (SGLT2) inhibition, which blocks reabsorption of glucose by the kidneys and increases its secretion into the urine 9 . These inhibitors have recently been FDA-approved, are effective at decreasing hyperglycaemia, and may decrease adverse cardiovascular outcomes in patients with type 2 diabetes 247 . However, they lack long-term safety data and may also cause urinary tract infections. Finally, bile acid sequestrants, which lower cholesterol by binding to bile acids, also lower blood glucose by an unknown mechanism 10 . However, as such agents bind bile acids in the intestine, they are also associated with adverse gastrointestinal effects.
Hepatic steatosis
Fatty liver disease.
can decrease inhibition of glycogen synthase 93 , this enzyme could also be targeted independently. A major regulatory kinase for glycogen synthase is glycogen synthase kinase 3 (GSK3), which phosphorylates and in activates glycogen synthase 94 . GSK3 levels and activity are increased in skeletal muscle of patients with type 2 diabetes 95 , and in the adipose tissue of obese diabetic mice 96 , suggesting that GSK3 contributes to insulin resistance.
Two maleimide compounds, SB-216763 and SB-415286, were discovered to be GSK3 inhibitors within the nanomolar range, with considerable specificity over other kinases 97 . These compounds were effective in activating glycogen synthase in human liver cells 97 , and suppressed phosphoenolpyruvate carboxykinase (PEPCK) and G6Pase in hepatoma cells 98 . Other specific and potent GSK3 inhibitors have also been used in vivo 99 . The amino pyrimidine derivatives CHIR-99021 and CHIR-98023 significantly increased glucose disposal in Zucker diabetic rats, which was accompanied by an increase in hepatic glycogen synthesis with no change in skeletal muscle glycogen synthesis 100 . These inhibitors also lowered blood glucose levels in db/db mice without causing hypo glycaemia 101 . In addition, the GSK3 peptide inhibitor L803-mts decreased blood glucose levels and PEPCK expression, and increased hepatic glycogen levels in ob/ob mice 102 . The effects of GSK3 inhibitors on blood glucose levels are promising, but there is reluctance to move these inhibitors to the clinic; this may stem from concerns over their potential activation of the oncogene β-catenin, although no studies have shown GSK3 inhibitors to be associated with increased tumorigenicity 103 . Moreover, potent GSK3 inhibition can lead to toxicity (as occurs with lithium treatment in the brain, causing motor deficits) 104 , so care must be taken to only mildly inhibit the enzyme. AZD1080, a GSK3 inhibitor from AstraZeneca, exhibited some success in limited phase I clinical trials for Alzheimer disease, but blood glucose levels were not measured 105 . Another GSK3 inhibitor, tideglusib (Noscria), was used in a phase II clinical trial for progressive supranuclear palsy 106 . Although tideglusib was generally found to be safe, it was not effective in treating progressive supranuclear palsy and the effects on blood glucose levels were not evaluated. Concerns were raised surrounding the irreversible nature of this inhibitor 107 , which may make toxicity more likely and its clinical use difficult.
Glucagon receptor antagonism
Increased secretion of glucagon from pancreatic α-cells -in addition to heightened hepatic sensitivity towards glucagon -contributes to the elevated hepatic glucose production observed in individuals with type 2 diabetes 108, 109 . Targeting the glucagon receptor may therefore be a promising approach for decreasing hepatic glucose production and reducing fasting plasma glucose levels 110 .
In support of this approach, two glucagon receptor peptide antagonists decreased blood glucose levels and improved insulin sensitivity in ob/ob mice and diet-induced obese mice 111 . In mice expressing human glucagon receptor, the glucagon antagonist compound 1 decreased blood glucose levels in response to glucagon administration 112 . In addition, NNC 25-0926, a potent glucagon antagonist with an IC 50 of 12 nm, blunted the glucagon-induced increase in blood glucose levels in fasting dogs 113 . Additionally, the selective and reversible competitive glucagon receptor antagonist compound 9m (also known as MK-0893 (Merck)) lowered glucagoninduced blood glucose levels in rhesus monkeys as well as in humanized ob/ob mice fed a high-fat diet 39 . Glucagon receptor antagonists have been used in several clinical studies. The orally available Bay 27-9955 (Bayer) decreased short-term fasting glucose levels without exhibiting any prominent side effects 37 , but was no longer pursued for clinical development for undisclosed reasons.
LGD-6972 (Ligand Pharmaceuticals) similarly demonstrated a dose-dependent decrease in fasting glucose in normal and diabetic subjects, and favourable safety profiles in a phase Ib clinical study; a phase II trial is currently underway to better assess its safety and efficacy 36 . In addition, once-daily dosing with PF-06291874 (Pfizer) decreased fasting and postprandial glucose levels in patients on metformin, with or without combined treatment with a sulfonylurea, for up to 28 days 35 . However, although this drug exhibited little risk of hypoglycaemia, it was associated with a small increase in low-density lipoprotein (LDL) cholesterol and amino transferase levels. A similar increase in LDL cholesterol levels was observed in clinical trials of MK-0893, resulting in discontinuation of this agent 38, 39 .
Although an initial short-term clinical study with LY2409021 (Eli Lilly) showed encouraging decreases in fasting and post prandial glucose levels, this also raised concerns as it led to a rise in aminotransferase levels 40 . However, a more recent, longer-duration phase II study indicated that doses of LY2409021 that are sufficient to lower fasting glucose levels only modestly increased aminotransferase levels, and clinical development is ongoing 41 . These results suggest that glucagon antagonists may be titrated for therapeutic use with minimal side effects.
Modulating pyruvate flux
Pyruvate carboxylase inhibition. Insulin has been found to decrease hepatic glucose production by suppressing pyruvate flux through inhibition of adipose lipolysis, which decreases levels of hepatic acetyl-CoA, a potent activator of pyruvate carboxylase 114 . Therefore, inhibiting pyruvate carboxylase may be a strategy for diabetes treatment. Indeed, in a study of human liver biopsy samples, pyruvate carboxylase levels correlated significantly with hyperglycaemia 115 . Furthermore, inhibition of pyruvate carboxylase through antisense oligonucleotide targeting in the liver and in adipose tissue of high-fat-fed and diabetic rats resulted in lowered blood glucose levels and reduced rates of gluconeogenesis 115 . Additionally, adiposity and hepatic steatosis were decreased owing to reduced glycerol synthesis. Although phenylalkanoic acids can inhibit pyruvate carboxylase, and phenylpropionic acid decreased gluconeogenesis at least acutely in normal and diabetic rats 116 , these compounds lack tissue specificity. Additionally, phenylalkanoic acids may inhibit insulin
Lactic acidosis
Increased acidity in the body due to a build-up of lactate; a potential complication associated with inhibition of hepatic gluconeogenesis.
secretion, as treatment of cultured β-cells and rat islets with phenylacetic acid decreased glucose-stimulated insulin release 117 . Therefore, although this is a promising antidiabetic strategy, improved pharmacological or nonpharmacological approaches would need to be developed to selectivity inhibit this enzyme in a clinical setting.
Inhibition of mitochondrial pyruvate import. Another method to inhibit pyruvate flux into gluconeogenesis is to block pyruvate transport across the inner mitochondrial membrane into the mitochondrial matrix, where it generates oxaloacetate for use in glucose production 118 . A heteroligomeric complex of mitochondrial pyruvate carrier 1 (MPC1) and MPC2 is necessary and sufficient for transport of pyruvate through this mechanism 119, 120 . Independent studies assessed the role of these proteins in the control of gluconeogenesis. Liver Mpc1-knockout mice exhibited compensatory increased glutamine usage and urea cycle activity, which also led to the production of oxaloacetate, preventing a decrease in basal gluconeogenesis 121 . However, despite this compensation, hyperglycaemia was decreased and glucose tolerance was improved in the Mpc1-knockout mice fed a high-fat diet. Similarly, knockout of hepatic MPC2 induced compensatory amino acid metabolism and decreased hyperglycaemia in db/db mice and streptozotocin-induced diabetic mice 122 . The effects of MPC1 and MPC2 on blood glucose levels in diabetes models suggest that pharmacological targeting of these proteins may represent a promising diabetes therapy. The established MPC inhibitor UK-5099 suppressed glucose production from primary hepatocytes 121 and increased glucose uptake into myocytes 123 . Intriguingly, TZD compounds
can also directly inhibit MPC and improve glucose handling in a PPARγ-independent manner 123, 124 . Specific targeting of MPC in the liver may therefore improve blood glucose levels without leading to undesirable side effects resulting from actions on other tissues, as can occur with TZDs. In addition, such liver-specific MPC blockade would prevent inhibition of pyruvate uptake into tissues that are critically dependent on glucose as a fuel source. However, the potential for compensatory effects would need to be carefully evaluated in a clinical setting, particularly with regard to the increase in glutamine metabolism, as glutamine anaplerosis and oxidation can help fuel the tricarboxylic acid (TCA) cycle and fatty acid synthesis that drive tumorigenesis 121, 125 .
Targeting gluconeogenesis enzymes
Inhibition of PEPCK and G6Pase. Two gluconeogenic enzymes with the potential to be targeted for diabetic treatment are PEPCK, which converts oxaloacetate to phosphoenolpyruvate (PEP), and G6Pase, which catalyses the conversion of glucose-6-phosphate to glucose. The expression of these enzymes is highly regulated by glucagon and insulin in correlation with gluconeogenic flux [126] [127] [128] [129] . In addition, PEPCK expression is dysregulated in diabetes, and a sevenfold increase in the expression of PEPCK results in hyperglycaemia in mice 130 . PEPCK has therefore been thought to be a rate-limiting enzyme for gluco neogenesis and has been implicated as a potential target to reduce hepatic glucose production and blood glucose levels. Indeed, inhibition of PEPCK by 3-mercaptopicolinic acid results in hypoglycaemia 131 . However, the notion that PEPCK is rate-limiting in gluconeogenesis has recently been challenged, particularly as neither PEPCK nor G6Pase levels are elevated in the livers of patients with type 2 diabetes 132 . Specifically, liver-specific Pepck-knockout mice maintain normal blood glucose levels even after 24 hours of fasting 133, 134 , as a result of increased extrahepatic gluconeogenesis and reduced whole-body glucose turn over 134 . In addition, the amount of PEPCK in the liver exhibits poor control over hepatic glucose production, but very strong control of flux through the TCA cycle, the inhibition of which ultimately leads to triglyceride accumulation in the liver 133, 135, 136 . These studies highlight the importance of PEPCK in cataplerosis (that is, the removal of TCA cycle intermediates), and suggest that it might also support the energetic demands of gluconeogenesis via maintenance of TCA cycle flux. Although the control strength of PEPCK on gluconeogenic flux is lower than that expected of a rate-limiting enzyme, small changes in PEPCK levels can still lead to decreased gluconeogenic flux 136 . Interestingly, in mice lacking G6Pase in the liver, normal blood glucose levels are maintained during prolonged fasting 137 . As noted for Pepck-knockout mice, this is due to increased levels of extrahepatic gluconeogenesis 137 . In addition, G6pc-knockout mice are protected from diet-induced obesity owing to increased energy expenditure in peripheral tissues 138 . The studies with genetic models of PEPCK and G6Pase imply that complete inhibition of one of these enzymes singularly in the liver might not be sufficient to reduce blood glucose levels in vivo in the non-diabetic state. However, these studies do not preclude the possibility that decreased activity of these genes may improve hyperglycaemia, particularly in the diabetic state. To this end, partial silencing of PEPCK by RNA interference (RNAi) decreased blood glucose levels and free fatty acid levels in diabetic mice while avoiding hepatic steatosis and lactic acidosis 104 . Moreover, PEPCK and G6Pase are part of a coordinated response to the fasting state, which involves many changes in cellular signalling, including upregulation of gluconeogenic pathways, a switch from glucose to fatty acid oxidation and increased autophagy, among others 139, 140 . Therefore, targeting this response (for example, by targeting post-translational modifications of PPARγ co-activator 1α (PGC1α), as described below), rather than directly inhibiting either enzyme alone, might prove to be a more effective strategy for controlling hyperglycaemia. Targeting PEPCK and G6Pase indirectly through modulation of its regulators may also allow for additional metabolic alterations, including redirection of carbon intermediates, which can circumvent potential problems associated with direct targeting of these enzymes.
FBPase inhibitors.
FBPase, which converts fructose-1,6-bisphosphate to fructose-6-phosphate, is another gluconeogenic enzyme with the potential to be inhibited for diabetes treatment. Treatment of diabetic rats with the direct FBPase inhibitor and phosphanate prodrug MB06322 (also known as CS-917; Metabasis Therapeutics) led to decreased hyperglycaemia without causing aberrant metabolic alterations 42 . This inhibitor was an 8,9-disubstituted purine that acts as an AMP mimetic to bind to the allosteric site of FBPase. Benzimidazole analogues with IC 50 values of less than 100 nM were developed, which lowered glucose levels in rats and inhibited human liver FBPase 43 . Further steps have been taken to determine whether this class of compounds could be developed for the clinic. Specifically, MB07803 is a second-generation FBPase inhibitor based on CS-917, which was used in a phase Ib clinical trial in patients with type 2 diabetes 44 . In this short-term study, blood glucose levels were lowered in the 6 hours following a 12-hour fast. However, some patients experienced nausea and vomiting at higher doses. Additional studies will need to be conducted regarding the longterm effects of this drug class, as well as the potential development of an FBPase inhibitor that does not induce gastrointestinal side effects.
Activation of PFK/FBPase 2.
A potent regulator of glycolytic and gluconeogenic flux is fructose-2,6-bisphosphate (F-2,6-P 2 ; also known as F-2,6-BP), which is a product of the bifunctional enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 (PFK/FBPase 2; also known as PFKFB2). Insulin stimulates the kinase activity of this bifunctional enzyme, which results in increased levels of F-2,6-P 2 and allosterically activates phosphofructokinase 1 (PFK1), which is responsible for catalysing the first committed step in glycolysis -conversion of fructose-6-phosphate to fructose 1,6-bisphosphate -and has the opposite effect to FBPase 141 . By contrast, glucagon stimulates the FBPase activity of the enzyme, resulting in reduced levels of F-2,6-P 2 and elevated gluconeogenesis 141 . In accordance with its importance in controlling glucose flux, increasing the levels of F-2,6-P 2 in the liver improves insulin sensitivity and lowers blood glucose levels in mice 142 , making the bifunctional enzyme a potential target to reduce hepatic glucose production. In addition, overexpression of the bifunctional enzyme in the mouse liver lowers blood glucose levels through suppression of hepatic glucose production 143 , further supporting the concept that activation of this enzyme by small molecules might have beneficial effects on glucose homeostasis.
Targeting transcription factors and co-activators
Targeting transcription factors and co-activators could be a potentially effective method for developing treatments for type 2 diabetes, as these regulators can affect entire pathways and responses that are physiologically regulated by fasting and feeding. However, transcription factors are frequently found in multiprotein complexes, and designing small molecules that potently change the activity of these multiprotein complexes can be difficult 144 . Various confounding factors include the large molecular area involved in protein -protein interactions, which may not contain ideal pockets for small molecules to bind; the large and flexible structure of co-activators, which can be accompanied by an unknown crystal structure; a lack of ligand-binding sites; and limited small-molecule libraries with properties that are ideal for targeting transcription 145, 146 . However, small molecules may allosterically affect protein-protein interactions to ultimately affect multiprotein complex activity, either by disrupting the integrity of the complex or by changing posttranslational modifications (PTMs) of specific subunits 147 . Indeed, there have been successful approaches targeting transcriptional proteins, including the identification of a direct inhibitor of steroid receptor coactivator protein 3 (SRC3; also known as NCoA3) through high-throughput screening of small molecules that alter SRC3-dependent transcription 145 . Moreover, modulating transcription factor activity -by interfering with the interaction between transcription factors and their cofactors -has been a major focus in drug development for the treatment of cancer 148, 149 .
PGC1α
. Several transcriptional regulators of liver metabolism have the potential to be pharmacologically targeted for the treatment of diabetes. PGC1α is a transcriptional co-activator that is activated in response to nutrient signals 150 . Initially, PGC1α was identified in brown adipose tissue as a cold-inducible co-activator of nuclear receptors 151 , with high expression observed in other metabolic tissues 151, 152 . PGC1α is a chief regulator of mitochondrial biogenesis and function, and, consistent with its cold-inducible status, it is an activator of mitochondrial uncoupling 153 . In the liver, PGC1α expression is modulated acutely by nutritional status, as it acts as a primary inducer of gluconeogenesis 154 . In the fed state, hepatic PGC1α levels are low and gluconeogenesis is suppressed 154 . Conversely, under fasting conditions, PGC1α levels are markedly enhanced to stimulate gluconeogenesis and fatty acid oxidative metabolism 154 . The induction of PGC1α under fasting conditions is achieved through the action of glucagon 155 (FIG. 3a) . When induced, PGC1α coactivates the glucocorticoid receptor, hepatic nuclear factor 4α (HNF4α) and forkhead box O1 (FOXO1), leading to PEPCK and G6Pase transcription 139, 154, 155 . In addition, PGC1α increases hepatic insulin resistance and fatty acid oxidation through the co-activation and induction of PPARα 156 . Insulin resistance is increased through PPARα-dependent upregulation of Tribbles homologue 3 (TRB3), which is a negative regulator of AKT, whereas fatty acid oxidation is enhanced by PPARα-driven transcription of genes involved in fatty acid oxidation 156 . This increase in fatty acid oxidation provides carbon substrates to the TCA cycle, which in turn contributes to increased gluconeogenic flux.
Several studies have investigated the role of PGC1α in regulating blood glucose levels in knockout or knockdown mouse models. Although one study found no change in gluconeogenesis or in Pepck and G6pc gene expression in liver-specific knockout mice , others determined that fasting hypoglycaemia occurs with homozygous knockout, heterozygous knockout and/or with RNAi-mediated PGC1α knockdown 156, 158, 159 . Another study found that PGC1α knockout specifically decreases glucose production owing to reduced gluconeogenic flux from PEP, . The discrepancy is likely to result from differences in the mouse models and strains used, but the majority of the evidence is in support of PGC1α as a regulator of blood glucose levels. Complete and chronic ablation of PGC1α may result in the activation of compensatory mechanisms that mask the effect of PGC1α inactivation; however, suppressing PGC1α in the liver has the potential to reduce glucose production.
In addition to its transcriptional regulation, PGC1α activity is regulated by PTMs, including phosphorylation 161, 162 , acetylation [163] [164] [165] [166] [167] and methylation 168 (FIG. 3a) . During fasting, induction of PGC1α in the liver is achieved through the action of glucagon, which increases the activity of cyclic AMP, protein kinase A (PKA) and CREB to increase PGC1α transcription 155 . Enhanced PGC1α expression is inhibited by the cyclin-dependent kinase (CDK) inhibitor p16
INK4A
, which decreases gluconeogenic gene expression through suppression of PKA activity 252 . Activated PGC1α co-activates the transcription of several transcription factor (TF) binding partners, including hepatic nuclear factor 4α (HNF4α), forkhead box O1 (FOXO1), and glucocorticoid receptor, to increase the transcription of target genes such as phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase). PGC1α activity can be altered by post-translational modifications (PTMs), including acetylation and phosphorylation (which decrease its activity) and methylation (which increases its activity). Insulin decreases PGC1α activity by increasing its phosphorylation by AKT and CDC2-like kinase 2 (CLK2), and insulin-induced S6 kinase (S6K) also inhibits PGC1α through phosphorylation. PGC1α acetylation is decreased by sirtuin 1 (SIRT1) and increased by general control of amino acid synthesis protein 5 (GCN5), the activity of which is increased by CDK4 and SIRT1, and inhibited by CBP/p300-interacting transactivator 2 (CITED2). PGC1α is methylated by protein arginine methyltransferase 1 (PRMT1). b | Regulation of FOXO activity. The TF FOXO is co-activated by PGC1α to increase the transcription of gluconeogenic genes. FOXO activity is modulated by PTMs, including phosphorylation by AKT, which leads to its polyubiquitylation and degradation, and removal of monoubiquitylation by ubiquitin-specific protease 7 (USP7), which decreases its transcriptional activity. FOXO can also be activated through deacetylation by histone deacetylase 3 (HDAC3) in response to insulin signalling. c | Regulation of cAMP-responsive element-binding protein (CREB) activity. CREB is a TF that increases gluconeogenic gene expression from cAMP-responsive elements (CREs) when activated by a co-activator such as p300, CREB-binding protein (CBP) or CREB-regulated transcription co-activator 2 (CRTC2). CREB activity is increased by phosphorylation at Ser133, which is enhanced by glucagon-stimulated PKA activity, which is inhibited by cryptochrome 1 (CRY1) and CRY2. CRE transcription can also be increased by glucagon through dephosphorylation of CRTC2, which increases its activity as a CREB co-activator, or inhibited by insulin-dependent salt inducible kinase 2 (SIK2)-mediated phosphorylation of CRTC2, decreasing its activity as a co-activator. CREB activity is inhibited by binding of the TF TCF7L2 to CREs, which blocks binding of CREB. Potential therapeutic strategies and agents targeting the activity of PGC1α, FOXO and CREB are shown in blue. Ac, acetylation; AMPK, AMP-activated protein kinase; aPKC, atypical protein kinase C; COP1, constitutive photomorphogenesis protein 1; Me, methylation; P, phosphorylation; SHP, small heterodimer partner; Ub, ubiquitylation.
Insulin suppresses PGC1α activity by increasing its phosphorylation at Ser570 by AKT 161 , and through AKT-induced CDC2-like kinase 2 (CLK2), which phosphorylates the PGC1α serine-arginine domain 162 . Serinearginine domain phosphorylation is also increased by insulin-induced S6 kinase (S6K), enabling decreased gluconeogenic activity of PGC1α specifically by interfering with its interaction with HNF4α 169 . PGC1α activity has been found to be increased by deacetylation and decreased by acetylation 163 . The deacetylation of PGC1α is regulated by fasting and feeding, as the activity of the deacetylase sirtuin 1 (SIRT1) and its interaction with PGC1α are enhanced during fasting 164 . Additionally, SIRT6 has been found to deacetylate general control of amino acid synthesis protein 5 (GCN5; also known as KAT2A), increasing its acetyltransferase activity towards PGC1α 165, 166 . PGC1α can also be acetylated by cyclin D1-cyclin-dependent kinase 4 (CDK4) -the activity of which is increased by feeding and in db/db mice -which activates GCN5 (REF. 167 ). A protein that has been discovered to deacetylate PGC1α, named CBP/ p300-interacting transactivator 2 (CITED2; also known as MRG1), is a glucagon-stimulated inhibitor of GCN5, and knockdown of hepatic CITED2 decreased gluconeogenesis in mice 170 . Additionally, PGC1α activity can be modified through methylation, with protein arginine methyltransferase 1 (PRMT1) stimulating the activity of PGC1α 168 . The regulation of PGC1α methylation during fasting and feeding has not yet been determined.
Owing to its robust effect on gluconeogenesis, drug targeting of PGC1α in the liver is a potentially appealing strategy for the treatment of type 2 diabetes. The most significant challenge associated with targeting PGC1α is achieving selective inhibition of its gluconeogenic function in the liver without inhibiting its effect on mitochondrial function in the liver and other metabolic tissues. However, potential strategies to possibly achieve this goal are multifold. One such strategy is to target specific PTMs of PGC1α that only affect its activity towards gluconeogenic targets, perhaps by targeting the interaction between PGC1α and HNF4α or FOXO1. This strategy is supported by the finding that S6K can specifically target the interaction of PGC1α with HNF4α 169 . Although manipulating specific protein-protein interactions or PTMs within a multiprotein complex is not a simple task, lessons learned from the regulation of other transcriptional complexes, such as the nuclear factor-κB (NF-κB) pathway, suggest that it may be achievable 171 .
Another strategy is to alter the stability or activity of PGC1α by targeting upstream regulators that are expressed relatively specifically in the liver. Utilizing existing inhibitors of PGC1α activators such as SIRT1 and AMP-activated protein kinase (AMPK) is of limited usefulness for decreasing gluconeogenesis, as these proteins have a broad arsenal of targets in addition to PGC1α 172, 173 . Furthermore, global inhibition of SIRT1 and/or AMPK would be detrimental, as these proteins have been found to beneficially alter metabolism to improve cardiac and skeletal muscle function, ageing and brain function, among other effects 174, 175 . However, other PGC1α regulators discussed above have the potential to be targeted in order to alter hepatic gluconeogenesis without aberrantly affecting other metabolic pathways. Additionally, several compounds were found to increase PGC1α expression through high-throughput screening in skeletal muscle cells, indicating that chemical modifiers of PGC1α expression could also be probed in the liver 176 . A small molecule named ZLN005 was discovered in a screen for compounds that increased PGC1α transcription in HEK293 cells, and was confirmed to activate its transcription in L6 myotubes 177 . When used in vivo in db/db mice, ZLN005 activated transcription in skeletal muscle as expected, but inhibited PGC1α transcription in the liver. The expression of G6Pase and PEPCK decreased while pyruvate tolerance improved. There was also no effect on mitochondrial gene targets in the liver. The mechanism of action of this drug is unclear, as it had no cell-autonomous effect on primary hepatocytes. However, these results suggest that it may be possible to therapeutically target PGC1α in specific tissues to achieve the desired inhibitory effects in the liver and stimulatory effects in skeletal muscle or adipose tissue. Further understanding of the precise mechanisms regulating PGC1α activity will aid in the development of potential liver-specific therapeutics.
FOXO proteins.
As indicated above, FOXO1 is a transcription factor that is co-activated by PGC1α in response to insulin in order to regulate hepatic gluconeogenesis 155 . Mammals express four evolutionally conserved FOXO proteins, named FOXO1, FOXO3A, FOXO4 and FOXO6 (REF. 178 ). Although the role of FOXO1 in gluconeogenesis is well established 155 , there is evidence that other FOXO proteins also contribute to this process. Mice with triple ablation of Foxo1, Foxo3 and Foxo4 have increased fasting hypoglycaemia and insulin sensitivity compared to mice with Foxo1 knockout alone, suggesting that FOXO3 and FOXO4 contribute to the control of gluconeogenesis 179 . Additionally, hepatic glucose output is increased in FOXO6-transgenic mice, whereas depletion of hepatic FOXO6 causes fasting hypoglycaemia, demonstrating that FOXO6 also takes part in regulating gluconeogenesis 180 . In addition to controlling gluconeogenesis, FOXO proteins have been shown to regulate hepatic lipid metabolism 181 . Foxo1 knockout alone does not alter lipid metabolism 182 , but hepatic steatosis and lipid secretion are increased in Foxo1-and Foxo3-double knockout mice 182 , while Foxo1-, Foxo3-and Foxo4-knockout mice exhibit hepatic lipid accumulation 183 . FOXO activity is distinctly controlled by PTMs, which has implications for hepatic glucose output. In particular, FOXO1, FOXO3A and FOXO4 are phosphorylated by AKT in response to insulin at three consensus sites 184 (FIG. 3b) . Phosphorylation at these sites enables binding by the 14-3-3 protein and subsequent FOXO polyubiquitylation and degradation. This phosphorylation by AKT is also dependent on binding to the scaffold protein WD40/ ProF, and this interaction is inhibited by atypical protein kinase C (aPKC) 185 . Ubiquitylation of FOXO1 can also be modulated by ubiquitin-specific protease 7 (USP7) 186 , which decreases monoubiquitylation of FOXO1 to deplete its transcriptional activity, and constitutive photomorphogenesis protein 1 (COP1), which acts as an E3 ubiquitin ligase to polyubiquitylate FOXO1 and increase its degradation 187 . Moreover, FOXO proteins are regulated by acetylation, whereby histone deacetylases HDAC4 and HDAC5 are phosphorylated by AMPK in response to insulin, leading to recruitment of HDAC3 and deacetylation and activation of FOXO transcription 188 . Targeting of FOXO proteins, either dependent on or independent of PGC-1α activity, may be a potential avenue for developing drugs for type 2 diabetes. Indeed, a direct FOXO1 inhibitor, named AS1842856, was discovered to bind and block FOXO1 transactivation, and was successful in decreasing fasting blood glucose levels in db/db mice without affecting wild-type mice 189 . Another compound found to inhibit FOXO1, named AS1708727, similarly decreased blood glucose and triglyceride levels when administered for 4 days to db/db mice 190 . Further investigation into the precise mechanism of action of these or similar compounds may yield insights into how to specifically target FOXO proteins in the liver. Additional studies regarding the nature of PTMs of FOXO proteins are likely to help in this endeavour. The design and development of drugs that would target multiple FOXO proteins would also need to consider the potential hepatic steatosis that can result from inhibition of FOXO proteins 182, 183 . CREB. cAMP-responsive element-binding protein (CREB) is a transcription factor that binds to cAMPresponsive elements (CREs) and alters gene transcription in various tissues, with known effects on neuronal plasticity, memory, inflammation and hepatic gluconeogenesis 191 . In the liver, glucagon activates protein kinase A PKA through cAMP to phosphorylate CREB at Ser133 (REF. 192 ), which enables it to interact with the co-activators p300 and CREB-binding protein (CBP) 193 (FIG. 3c) . Glucagon also stimulates dephosphorylation of CREB-regulated transcription co-activator 2 (CRTC2; also known as TORC2), which then co-activates CREB on gluconeogenic genes 194 . The involvement of CREB in controlling glycaemia was demonstrated in Crebknockout mice, which exhibited fasting hypoglycaemia 195 . PGC1α was also found to be a direct transcriptional target of CREB, and its expression is increased with chronic CREB activation during prolonged fasting 195 . In addition to its effects on gluconeogenesis and fatty acid oxidation through PGC1α, CREB increases the flux of fatty acids towards the TCA cycle by decreasing lipogenesis through the inhibition of PPARγ 196 . Several other proteins have been shown to modulate CREB activity. Small heterodimer partner (SHP) is a transcriptional repressor that binds to CREB to inhibit its interaction with CRTC2 (REF. 197 ). Insulin also inhibits CRTC2 through salt inducible kinase 2 (SIK2)-mediated phosphorylation, leading to CRTC2 degradation and reduced CREB-mediated transcription 198 . TCF7L2 is a transcription factor that binds to CREs to block their occupation by CREB 199 . Circadian proteins have also been recognized to have a role in the regulatory control of CREB and gluconeogenesis. Specifically, cryptochrome 1 (CRY1) and CRY2 decrease the gluconeogenic gene programme by blocking glucagon-induced increases in cAMP and PKA-mediated phosphorylation of CREB 200 . As CREB exerts effects on other tissues, particularly the brain, and affects PGC1α, it is important to specifically target CREB in the liver. Targeting co-activators or inhibitors of CREB, or the interaction of CREB with these proteins, is likely to be a more feasible approach than directly inhibiting CREB activity. In this regard, a bromodomain inhibitor named CBP30 has been developed that selectively targets CBP and p300 (REF. 201) and exerts anti-inflammatory effects. Additionally, the protein-protein interaction between CREB and CBP was successfully inhibited by the small molecule KG-501 (2-naphthol-AS-E-phosphate), which decreased cAMP-responsive gene induction 202 . The potential of these agents to decrease gluconeogenesis could be explored.
Although CRTC2 has not been pharmacologically targeted, Crtc2-knockout mice exhibited decreased hepatic glucose production with improved insulin sensitivity, and without apparent neurological deficits 203 . In addition, selective drug targeting of CRY proteins has been achieved by the carbazole derivative KL001, which interacts with CRY proteins and prevents their ubiquitin-dependent degradation 204 . This compound effectively decreased gluconeogenic gene expression and glucose production after glucagon treatment in primary hepatocytes, although it was not utilized in a mouse model.
Together, these observations suggest that it may be feasible to target the CREB pathway, through its co-activators or inhibitors, in order to selectively target gluconeogenesis in the liver.
C/EBPα and C/EBPβ. CCAAT/enhancer-binding protein-α (C/EBPα) is a transcription factor that increases gluconeogenic gene expression, and its loss results in hypoglycaemia-induced neonatal death within 8 hours of birth 205 . This regulation of gluconeogenesis is PGC1α-independent, but dependent on particular C/EBPα residues to control subsets of target genes 206 . Specifically, three consensus residues for GSK3 phosphorylation (Thr222, Thr226, and Ser230) were shown to be insulin-responsive, and knock-in mouse models were generated in which these residues were mutated to alanines 206 . These knock-in mice exhibited elevated hepatic expression of PEPCK and G6Pase in conjunction with glucose intolerance, demonstrating that these residues are responsible for regulating gluconeogenic genes and glucose tolerance without affecting lipid metabolism. Another study demonstrated that phosphorylation of C/EBPα at Ser21 by p38 mitogen-activated protein kinase (p38 MAPK) led to increased PEPCK expression in hepatoma cells 207 , suggesting that liver-specific inhibition of this phosphorylation site may decrease gluconeogenesis. The related family member C/EBPβ also modulates gluconeogenic gene expression, although it is not necessary for basal regulation 208 . Instead, C/EBPβ decreases hyperglycaemia and gluconeogenesis in streptozotocin-induced diabetes, with decreased expression of gluconeogenic genes 208 .
The partial redundancy in the functions of C/EBPα and C/EBPβ makes them potentially appealing drug targets for type 2 diabetes, particularly C/EBPβ, which has not been found to affect basal gluconeogenesis but instead partially reverses hyperglycaemia 208 . Therefore, theoretically, a drug that specifically inhibits C/EBPβ may be able to reduce blood glucose levels without causing hypoglycaemia. Additionally, drug targeting of specific phosphorylation sites on C/EBPα may have the ability to fine-tune the control of gluconeogenesis by C/EBPα without affecting other metabolic pathways, as modulation of GSK3 phosphorylation sites affects gluconeogenic gene expression without altering lipid metabolism 206 . Although technically challenging, small molecules that inhibit specific phosphorylation sites of target proteins have been identified for other pathways through screening methods such as phosphopeptide binding to fusion proteins 209 .
REV-ERBs and RORs. REV-ERBs and retinoic acid receptor-related orphan receptors (RORs) are nuclear receptors that are involved in several cellular processes, notably metabolism and circadian rhythm regulation 210 . REV-ERBs constitutively repress transcription at ROR response elements through the binding of co-repressors. In response to binding by haem, REV-ERBα suppresses gluconeogenic genes and glucose production in HepG2 CRMP, controlled-release mitochondrial protonophore; db/db, leptin receptor-deficient mouse model of diabetes; DNP-ME, protonophore 2,4-dinitrophenol (DNP) methyl ester; FBPase, fructose-1,6-bisphosphatase; FOXO1, forkhead box O1; GKRP, glucokinase regulatory protein; GSK3, glycogen synthase kinase 3; IKKβ, IκB kinase β; LDL, low-density lipoprotein; mGPD, mitochondrial glycerophosphate dehydrogenase; ob/ob, leptin-deficient mouse model of obesity and insulin resistance; PPAR, peroxisome proliferator-activated receptor; PTP1B, protein tyrosine phosphatase 1B; RORα, retinoic acid receptor-related orphan receptor-α.
cells through increased recruitment of the nuclear receptor co-repressor-histone deacetylase 3 (NCoR-HDAC3) complex 211 . The ROR family, which includes RORα, RORβ and RORγ, activates transcription at ROR response elements through the recruitment of co-activators such as PGC1α 212 and steroid receptor co-activator 2 (SRC2) 213 . Loss of RORα leads to fasting hypoglycaemia and decreased expression of gluconeogenic genes in the liver 214 . Manipulation of REV-ERBs and RORs may be of therapeutic benefit for type 2 diabetes. Activation of REV-ERBs with agonists or inhibition of RORα with inverse agonists has the potential to inhibit hepatic gluconeogenesis 215 . The REV-ERB agonist GSK4112, a tertiary amine, was found to decrease the expression of gluconeogenic genes and glucose output in hepatocytes, but it has been reported to lack plasma exposure 216 . Two additional compounds, SR9011 and SR9009, were discovered through high-throughput screening as synthetic activators of REV-ERB repressor activity 217 . Administration of these drugs to wild-type mice for 6 days significantly altered metabolic gene expression in the liver. Although gluconeogenic gene expression was not measured in this study, hepatic PGC1α mRNA expression was repressed, which is indicative of gluconeogenesis inhibition. Moreover, treatment of dietinduced obese mice with SR9009 caused weight loss, with lowered levels of plasma glucose and lipids. The selective RORα inverse agonist and benzenesulfonamide SR3335 suppressed gluconeogenic gene expression in HepG2 cells, and decreased glucose production and plasma glucose levels in a mouse model of diet-induced obesity 218 . SRC1 and SRC2. SRC1 and SRC2 are members of the p160 family of co-activators that control the transcription of metabolic gene networks 219 . SRC1 is needed to induce the gluconeogenic programme during the transition from the fed to the fasting state, and Src1-knockout mice develop hypoglycaemia without exhibiting decreases in insulin secretion or sensitivity 220 . The effect on gluconeogenesis is dependent on increased expression and transcriptional activity of C/EBPα 220 . SRC2 also regulates gluconeogenesis, specifically through co-activation of RORα, leading to increased expression of G6Pase 213 . Emphasizing the importance of SRC2 in controlling liver glucose metabolism, knockout of Src2 in mice leads to a Von Gierke's disease phenotype, which is characterized by fasting hypoglycaemia and increased glycogen storage 213 . Drug targeting of SRC1 and SRC2 may be feasible, as the drug gossypol was discovered to specifically inhibit SRC1 and SRC3, resulting in cancer cell toxicity 221 . Additionally, a direct inhibitor of SRC3 has been identified 145 . However, potent inhibition of these coactivators would be undesirable owing to the development of fasting hypoglycaemia, and the potential toxicity to non-cancer cell types is unknown. Instead, a drug exhibiting partial and specific inhibition of SRC1 and/or SRC2 may be beneficial for treating type 2 diabetes. Such inhibition may potentially be accomplished by targeting PTMs of SRC1 and SRC2, as the stability, intracellular localization and transcription factor specificity and activation of these proteins has been found to be regulated by PTMs, including phosphorylation, ubiquitylation, acetylation and methylation 219 . This approach may enable the activity of these proteins to be fine-tuned to decrease blood glucose levels to desirable levels without inducing hypoglycaemia or other toxic side effects.
Mitochondrial uncoupling
Another strategy for targeting hepatic glucose output is to enhance glucose utilization in the liver by altering mitochondrial uncoupling. Uncoupling of the mitochondria diffuses the proton gradient across the inner mitochondrial membrane that is used to drive ATP synthesis, leading to the release of heat and increased consumption of metabolic substrates used by the TCA cycle to fuel oxidative phosphorylation 222 . Both fatty acid and glucose oxidation are thus increased by mitochondrial uncoupling. Although the mitochondrial protonophore 2,4-dinitrophenol (DNP) has been known for many years to cause weight loss, it was found to be toxic and even lethal when used clinically owing to its capacity to induce hyperthermia 223 . To address this, a DNP derivative (DNP-methyl ester, or DNP-ME) was developed that can only be metabolized by the liver, and its administration to diabetic rats decreased fasting levels of plasma glucose, triglycerides and insulin, and also decreased glucose production, while improving glucose tolerance 224 . The direct effects of DNP-ME on the liver also indirectly reduced muscle fat content and improved muscle insulin sensitivity 224 . Furthermore, a controlled-release orally available version of DNP -controlled-release mitochondrial protonophore (CRMP) -was developed, which induces mild hepatic uncoupling over a much longer time-frame 225 . Administration of CRMP to wild-type or Zucker diabetic fatty rats fed a high-fat diet lowered levels of plasma glucose, triglycerides and insulin, and decreased glucose production, while improving glucose tolerance. These compounds highlight the potential of utilizing mild oral hepatic uncouplers as an antidiabetic therapeutic strategy to increase substrate oxidation by the liver and thus decrease gluconeogenesis and lower blood glucose levels.
Challenges in targeting liver glucose homeostasis
It is generally accepted that increased hepatic glucose production, due to enhanced gluconeogenesis, is the major contributor to the increased blood glucose levels observed in patients with diabetes 71, [226] [227] [228] [229] . Directly targeting glucose production or storage may therefore represent an effective approach to regulating blood glucose levels. Inhibiting gluconeogenic and glycogenolytic enzymes would provide the most direct route of decreasing glucose production by the liver; accordingly, there are drugs under investigation that target these enzymes (TABLE 1) . Metformin, the first-line drug for the treatment of diabetes (despite its disputable mechanism of action), is believed to reduce blood glucose levels by decreasing gluconeogenesis and hepatic glucose production 4 , further supporting the notion that targeting liver glucose metabolism is a useful approach to control
Insulin secretagogues
Agents that increase insulin release from the pancreas.
hyperglycaemia. Novel diabetes drugs targeting glucose homeostasis in the liver would most probably be administered in combination with existing type 2 diabetes drugs, such as metformin and SGLT2 inhibitors, to achieve sustained normal blood glucose levels and to allow for the use of lower drug concentrations in order to avoid side effects
.
Modulating glucose homeostasis in the liver presents a myriad of challenges and potential advantages when considering novel treatments for type 2 diabetes. Decreasing hepatic glucose production could strongly inhibit blood glucose levels but hypoglycaemia must be avoided, and designing a drug that specifically targets the liver without affecting other tissues can be challenging. Therefore, potency and specificity are two key concerns when developing these drugs for in vivo administration. The potency of drugs that target enzymes involved in hepatic metabolism must be carefully considered, as hypoglycaemia or aberrant perturbations in liver fat metabolism can result from high levels of enzyme inhibition, as occurs with knockout of PEPCK and G6Pase 134, 230, 231 . Potent targeting of these enzymes in extrahepatic tissues can also result in metabolic dysfunction in other tissues, as observed in kidney-specific G6pc-knockout mice, which have renal lipid accumulation and glycogen overload 232 . One potential avenue to avoid hypoglycaemia is to target proteins that decrease hyperglycaemia without affecting basal blood glucose levels, such as glycogen phosphorylase or C/EBPβ 27, 208 . Targeting enzymes that are expressed predominately in the liver, such as G6Pase, is one obvious approach to increasing specificity 233 . Another potential strategy to increase tissue specificity is to modify drugs so that they can be metabolized only by the liver, as demonstrated in the development of the DNP derivative discussed above 224 . The development of this liver-specific DNP mitochondrial uncoupler also revealed a more indirect method of decreasing glucose production in the liver by increasing the oxidation of metabolic substrates in the liver. This drug targets the liver specifically, but it also has beneficial extrahepatic secondary effects such as decreased fat and improved insulin sensitivity in muscle tissue. Titrating a therapeutic to generate mild uncoupling without inducing toxicity will be a particular challenge for translating this class of drug to the clinic.
Modulation of co-activators and transcriptional regulators of metabolic enzymes -such as PGC1α, C/EBPs and others discussed above -could represent an effective method of lowering blood glucose levels. However, achieving liver specificity when modifying these proteins, potentially through liver-specific regulation of PTMs or tissue-specific regulation of downstream effectors, would be extremely important given the effects of these proteins on metabolism and other processes in other tissues.
In addition to the potential for hypoglycaemia, other possibly detrimental effects of targeting hepatic glucose production should be considered, including the risk of redirecting carbons to triglyceride or cholesterol synthesis. This redirection in anaplerotic flux could potentially lead to aberrant increases in lipogenesis and hepatic steatosis, or increased cholesterol. Despite its known effects on inhibiting gluconeogenesis, metformin does not increase triglycerides or blood glucose levels 234 , suggesting that inhibition of gluconeogenesis does not necessarily lead to aberrations in these parameters. However, novel drug targets would need to be carefully evaluated for their potential effects on triglycerides and cholesterol. Recent technical advances using 13 C labelling combined with 13 C magnetic resonance spectroscopy could be useful in detecting hepatic fatty acid oxidation in human livers in vivo to determine the effects of candidate drugs on the TCA cycle and anaplerotic flux 235 . Another potential complication of gluconeogenesis inhibition is lactic acidosis, as anaerobic respiration increases and may lead to lactate accumulation. The incidence of lactic acidosis has been explored with metformin. As metformin is renally cleared, the drug may accumulate in the kidneys of patients with renal disease, leading to lactic acidosis. However, metformin is not elevated above the therapeutic range in patients with renal failure 236 . Only a slight increase in lactic acidosis was found to occur with metformin treatment in these patients, with no substantial risk demonstrated in patients with mild to moderate kidney disease. Lactic acidosis is probably not a substantial risk in patients Combining novel and existing diabetes therapies that target different mechanisms of glucose homeostasis control could lead to enhanced effects on blood glucose. Indeed, combinations of existing diabetes drugs are already used in the clinic to achieve the desired reduction in blood glucose levels. Often, metformin is used first; however, in most patients, glycaemic control declines over time, making combination therapy an essential approach 75 . Metformin is usually combined with one or two drugs from different classes, including insulin, sulfonylureas, thiazolidinediones (TZDs), sodium-glucose co-transporter 2 (SGLT2) inhibitors, dipeptidyl peptidase 4 (DPP4) inhibitors and glucagon-like peptide 1 (GLP1) agonists 248, 249 . Clinically, considerations regarding what combinations to use involve assessment of efficacy, side effects, contraindications, cost, the complexity of dosing if multiple daily injections are necessary, and patient aversion to using injectable medications, as is needed for insulin and GLP1 agonists 250 . Novel diabetes drugs targeting glucose homeostasis in the liver would most probably be used in combination with existing type 2 diabetes drugs, such as metformin, to allow the use of lower drug concentrations to avoid side effects, or to prolong the antidiabetic effect. However, as metformin also targets glucose homeostasis in the liver, such novel agents may be particularly beneficial in decreasing hyperglycaemia when used in combination with drugs that target other mechanisms.
Combining novel drugs targeting hepatic glucose production with insulin sensitizers, like TZDs, which cannot result in uncontrolled insulin secretion, may impose lower risks of hypoglycaemia compared with insulin secretagogues such as GLP1 agonists. However, water retention, heart failure and weight gain are all known possible side effects of TZDs, which must be carefully considered. Although increased lactic acidosis is a potential concern when inhibiting hepatic glucose output, combination with TZDs, which increase the activity of pyruvate dehydrogenase, can ameliorate lactic acidosis by increasing lactate entry into the tricarboxylic acid (TCA) cycle 251 . This highlights an additional beneficial outcome of combination therapya more balanced effect on total energy metabolism that might improve overall glycaemic control outcomes. SGLT2 inhibitors that reduce glucose reabsorption by the kidney and increase its secretion, like TZDs, do not result in increased insulin secretion, and thus also impose a lower risk of hypoglycaemia. Combined treatment with SGLT2 inhibitors may therefore efficiently complement the action of drugs targeting hepatic glucose output. using drugs to inhibit gluconeogenesis, unless pharmacokinetic data reveal that a particular drug accumulates in tissues above the therapeutic range, which must be tested systematically.
Conclusions and future directions
Despite the existence of several antidiabetic drugs, type 2 diabetes remains a widespread medical burden. Targeting gluconeogenesis or glucose homeostasis in the liver is an appealing strategy for developing new diabetes therapeutics. Although metformin is currently the most widely used diabetes drug and works at least primarily through the inhibition of gluconeogenesis, its mechanism of action has not been fully clarified and it can cause gastrointestinal side effects; moreover, it typically must be used as a combination therapy for long-term sustainability 4, 11, 75 . Therefore, there is room for novel therapeutic agents that specifically inhibit hepatic glucose output.
Numerous molecular pathways in the liver contributing to glucose production have the potential to be targeted pharmacologically to decrease blood glucose levels. Efforts to generate drugs that directly inhibit the metabolic enzymes of gluconeogenesis and glycogenolysis are most advanced. There is also a wealth of targets within additional regulatory pathways, including PGC1α, FOXO proteins, CREB, C/EBPs, RERs, RORs and SRC proteins, that have the potential to be therapeutically modulated to regulate gluconeogenesis. Hepatic glucose output could also be inhibited by administering a liver-specific mitochondrial uncoupler. Although concerns about potency, tissue selectivity and undesirable metabolic effects such as lactic acidosis must be addressed, further investigation into specific methods of pharmacologically targeting these pathways in the liver are likely to be fruitful in the search for new drugs for type 2 diabetes.
